Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metatropic dwarfism × Cilengitide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 11 Gliosarcoma 5 Brain Neoplasms 5 Astrocytoma 4 Recurrence 3 Oligodendroglioma 3 Lymphoma, Follicular 3 Prostatic Neoplasms 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Optic Nerve Glioma 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell, Marginal Zone 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Immunoblastic Lymphadenopathy 2 Hodgkin Disease 2 Glioma 2 Diffuse Intrinsic Pontine Glioma 2 Carcinoma, Non-Small-Cell Lung 2 Burkitt Lymphoma 2 Waldenstrom Macroglobulinemia 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Sezary Syndrome 1

Interventions

Vinorelbine 1 Genz-644282 1 Gemcitabine 1 Everolimus 1 Drug Therapy 1 Cisplatin 1 Cilengitide 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00842712 2017-01-13

CERTO

Merck KGaA, Darmstadt, Germany

Phase 2 Completed

232 enrolled 17 charts

Metatropic dwarfism, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡